Literature DB >> 16199099

Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.

Rebecca M Ledford1, Marc S Collett, Daniel C Pevear.   

Abstract

Recent phylogenetic analyses of the deduced amino acid sequence of the major viral capsid protein (VP1) of all human rhinovirus (HRV) serotypes revealed two distinct species within the genus: species A (75 serotypes) and species B (25 serotypes). Pleconaril is a novel capsid inhibitor of HRVs. All 75 species A serotypes and 18 of the 25 species B serotypes are susceptible to inhibition by pleconaril in cell culture. The seven resistant serotypes are HRV-4, -5, -42, -84, -93, -97 and -99. We were interested in understanding the genetic basis for phenotypic resistance to pleconaril among these naturally occurring viruses. We compared the 25 amino acids of VP1 that comprise the drug-binding pocket of susceptible and resistant species B viruses. A consistent difference was observed at two positions: the vast majority of susceptible viruses had tyrosine and valine at VP1 residues 152 and 191, respectively (Y(152) and V(191)); all resistant viruses had phenylalanine and leucine at these positions (F(152) and L(191)). HRV-14, a pleconaril susceptible virus, has a drug-binding pocket amino acid composition that differs from the naturally resistant HRV-5 and HRV-42 only at these two positions. To gain further insight into the role of these specific residues in natural resistance to pleconaril, we substituted the amino acids at these two positions individually and in combination in an infectious clone of HRV-14 and tested the rescued virus for susceptibility to pleconaril and virion stability. The results indicate that substitution of V(191) to Leu in HRV-14 has a profound negative impact on drug susceptibility but that full resistance to pleconaril is only seen when combined with Phe at position 152 in a HRV-14 double variant (F(152), L(191)). These data identify L(191) in species B HRV as a potentially key residue in conferring significantly reduced susceptibility to pleconaril. These results may be useful in distinguishing naturally occurring viral resistance to pleconaril from treatment-emergent resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199099     DOI: 10.1016/j.antiviral.2005.08.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  22 in total

1.  Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.

Authors:  Chris Mello; Esmeralda Aguayo; Madeleine Rodriguez; Gary Lee; Robert Jordan; Tomas Cihlar; Gabriel Birkus
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance.

Authors:  Holly A Basta; Shamaila Ashraf; Jean-Yves Sgro; Yury A Bochkov; James E Gern; Ann C Palmenberg
Journal:  Virology       Date:  2013-10-20       Impact factor: 3.616

3.  Rhinovirus genome evolution during experimental human infection.

Authors:  Samuel Cordey; Thomas Junier; Daniel Gerlach; Francesca Gobbini; Laurent Farinelli; Evgeny M Zdobnov; Birgit Winther; Caroline Tapparel; Laurent Kaiser
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

4.  Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Authors:  Liang Sun; Adam Meijer; Mathy Froeyen; Linlin Zhang; Hendrik Jan Thibaut; Jim Baggen; Shyla George; John Vernachio; Frank J M van Kuppeveld; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts; Leen Delang
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

5.  In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Authors:  S L Binford; P T Weady; F Maldonado; M A Brothers; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

Review 6.  Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.

Authors:  Eunüs S Ali; Harinda Rajapaksha; Jillian M Carr; Nikolai Petrovsky
Journal:  Antiviral Res       Date:  2016-07-13       Impact factor: 5.970

7.  Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma.

Authors:  Yue Liu; Marchel G Hill; Thomas Klose; Zhenguo Chen; Kelly Watters; Yury A Bochkov; Wen Jiang; Ann C Palmenberg; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-11       Impact factor: 11.205

8.  Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.

Authors:  Jiri Wald; Marion Pasin; Martina Richter; Christin Walther; Neann Mathai; Johannes Kirchmair; Vadim A Makarov; Nikolaus Goessweiner-Mohr; Thomas C Marlovits; Irene Zanella; Antonio Real-Hohn; Nuria Verdaguer; Dieter Blaas; Michaela Schmidtke
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-28       Impact factor: 11.205

9.  Complete coding sequence characterization and comparative analysis of the putative novel human rhinovirus (HRV) species C and B.

Authors:  Piyada Linsuwanon; Sunchai Payungporn; Kamol Suwannakarn; Thaweesak Chieochansin; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Virol J       Date:  2011-01-07       Impact factor: 4.099

10.  Anti-human rhinoviral activity of polybromocatechol compounds isolated from the rhodophyta, Neorhodomela aculeata.

Authors:  Soon-Hye Park; Jae-Hyoung Song; Taejung Kim; Woon-Seob Shin; Gab Man Park; Seokjoon Lee; Young-Joo Kim; Pilju Choi; Heejin Kim; Hui-Seong Kim; Dur-Han Kwon; Hwa Jung Choi; Jungyeob Ham
Journal:  Mar Drugs       Date:  2012-10-10       Impact factor: 6.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.